General Administration of Sport of China

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, August 10, 2023
EUA, Database, Omicron, Drug development, IV, SG, Conference call, Serum, SARS-CoV-2, General Administration of Sport of China, COVID-19, Clinical trial, Research, Cohort study, Risk, Webcast, R, Immunodeficiency, FDA, Research and development, Conference, Safety, Vaccine, Pharmaceutical industry, Cryptocurrency

ET

Key Points: 
  • ET
    WALTHAM, Mass, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the quarter ended June 30, 2023, and recent business highlights.
  • “I am very excited with the progress we made in the second quarter.
  • Appointed Sara Cotter to board of directors: In July 2023, Invivyd appointed Sara Cotter to its board of directors.
  • Basic and diluted net loss per share was $0.46 for the quarter ended June 30, 2023, compared to $0.47 for the comparable period in 2022.

Noodles & Company Announces Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
External commercial borrowing, Capital expenditure, Restaurant, NDLS, Table, Share repurchase, Comparable, Bank statement, Noodles & Company, General Administration of Sport of China, AUV, GAAP, Chicken parmesan, Deleveraging, Public expenditure, EBITDA, Traction, Depreciation, Mount Boennighausen, Intervention AUV, Capital, Webcast, Growth, EPS, Adjustment, Hand, Environment, Total, Mobile phone, Video game, Cryptocurrency, Lithium, Bookkeeping, Fast food, Security (finance), Car rental, Risk management

BROOMFIELD, Colo., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for its second quarter ended July 4, 2023.

Key Points: 
  • BROOMFIELD, Colo., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for its second quarter ended July 4, 2023.
  • Key highlights for the second quarter of 2023 versus the second quarter of 2022 include:
    Total revenue decreased 4.5% to $125.2 million from $131.1 million in the second quarter of 2022.
  • Operating margin declined to (0.2)% in the second quarter of 2023 from 1.4% in the second quarter of 2022.
  • Noodles & Company will host a conference call to discuss its second quarter financial results on Wednesday, August 9, 2023 at 4:30 PM Eastern Time.

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 9, 2023
B cell, Heart, Patent, Priority review, Communication, Research and development, PKP2, Investment, Survival, Clinical trial, ARVC, Pharmacokinetics, Mutation, Fast Track, G&A, Heart failure with preserved ejection fraction, Trademark, Accelerated approval (FDA), AAV, SGLT2, R, Hypertrophy, HDAC6, Tubulin, Fibrosis, Investigational New Drug, American Heart, Administration, BCVS, Cardiomyopathy, Toxicity, Arrhythmia, Acetylation, FDA, General Administration of Sport of China, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, HCM, Phenotype, Gene, MYBPC3, Food, Safety, Pharmaceutical industry, Vaccine, Tenaya

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.

Key Points: 
  • Second Quarter Cash and Investments of $152 Million;
    SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.
  • Tenaya anticipates dosing its first patient in the “MyPeak-1” Phase 1b multi-center, open-label, dose-escalation clinical trial of TN-201 during the third quarter of 2023 (ClinicalTrials.gov #NCT05836259).
  • Non-cash stock-based compensation included in G&A expense was $2.1 million for the quarter ended June 30, 2023.
  • Net Loss: Net loss for the quarter ended June 30, 2023, was $33.3 million, or $0.45 per share.

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023
Vaccine, Exercise, Advisory Committee on Immunization Practices, Immunization, OPA, Research and development, Streptococcus, University, Life, Investment, IPD, Safety, Public, Advisory Committee, Licensure, G&A, Research, National Institutes of Health, Payment Card Industry Security Standards Council, Bangladesh Technical Education Board, Stage 2, History of the University of Maryland, College Park, Data monitoring committee, Breakthrough therapy, Genetically modified bacteria, Death, PCV20, Administration, SAN, Breakthrough, Rocket launcher, Infant, Ageing, Growth, PCV, R, FDA, General Administration of Sport of China, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Family, Announcement, Food, Pharmaceutical industry, Cryptocurrency, Shigella

SAN CARLOS, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • “Our strong balance sheet provides a solid foundation as we advance our PCV franchise and pipeline programs.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Clearance of the adult IND application by the FDA in the fourth quarter of 2023 following submission.
  • The June 30, 2023 amount includes the $545.3 million in net proceeds from the follow-on offering completed in April 2023.

Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 8, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Research and development, Half-life, Pharmacokinetics, Woman, G&A, Trial of the century, Net, Congress, Corporation, Patient, Administration, Risk, Thrombosis, Poster, Pregnancy, R, Rare, General Administration of Sport of China, International Society, Safety, Cryptocurrency, Pharmaceutical industry, Rare-earth element

Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent program and corporate developments.

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent program and corporate developments.
  • In the fourth quarter of 2023, we plan to complete the toxicology program for RLYB212, and share the results from the multiple dose cohort of our ongoing Phase 1 study for RLYB212.
  • Second Quarter 2023 Financial Results:
    Research & Development (R&D) Expenses: R&D expenses were $13.1 million for the second quarter of 2023, compared to $10.1 million for the same period in 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $7.0 million for the second quarter of 2023, compared to $7.5 million for the same period in 2022.

AbCellera Reports Q2 2023 Business Results

Retrieved on: 
Thursday, August 3, 2023
Biotechnology, Pharmaceutical, Health, Sales & Marketing Executives International, Webcast, AbCellera, Growth, R, Partnership, Research and development, S&M, General Administration of Sport of China, G&A, Research, Investment, Administration

AbCellera started discovery on an additional five partner-initiated programs to reach a cumulative total of 106 partnered program starts in Q2 2023 (up from 88 on June 30, 2022).

Key Points: 
  • AbCellera started discovery on an additional five partner-initiated programs to reach a cumulative total of 106 partnered program starts in Q2 2023 (up from 88 on June 30, 2022).
  • Revenue – Total revenue was $10.1 million, compared to $45.9 million in Q2 2022.
  • The partnership business generated research fees of $9.8 million, compared to $12.5 million in Q2 2022.
  • AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, August 2, 2023
Intercept, Workforce, FXR, EASL, Bezafibrate, Therapy, NASH, Hepatology, Serum, PBC, Cholestasis, General Administration of Sport of China, Pharmacokinetics, Biomarker, Sale, Congress, Shanda, SAH, Patient, Intercept Pharmaceuticals, OCA, Mullard 5-10, Growth, Depreciation, Fatty liver disease, European Association for the Study of Diabetes, Research, FDA, Conference, Total, Safety, Pharmaceutical industry, Rare-earth element, Security (finance), Silviculture, Liver, FRESH, Obeticholic acid

Selling, general and administrative expenses increased to $53.3 million in the second quarter of 2023, from $40.0 million in the prior year quarter.

Key Points: 
  • Selling, general and administrative expenses increased to $53.3 million in the second quarter of 2023, from $40.0 million in the prior year quarter.
  • Research and development expenses decreased to $37.3 million in the second quarter of 2023, from $44.8 million in the prior year quarter.
  • In the second quarter 2023, Intercept reported a net loss from continuing operations of $5.8 million, a decrease compared to a net loss from continuing operations of $20.3 million in the second quarter 2022.
  • ET
    The conference call and webcast discussing the Company’s second quarter 2023 financial results will take place on August 2, 2023, at 8:30 a.m.

Enhance Global Collaboration and Connectivity via E-Sports Competition: Perfect World CEO

Retrieved on: 
Tuesday, August 1, 2023
General Administration of Sport of China, Hangzhou, Social, Perfect World, DOTA, Culture, CS, IP, TI9, Sport, Development, Conference, AR, DOTA 2, Tourism, Creative industries, Entertainment

SHANGHAI, Aug. 1, 2023 /PRNewswire/ -- Dr. Robert H. Xiao, CEO of Perfect World and Perfect World E-sports & its platform segment, attended and addressed the 2023 Global Esports Conference on July 28 in Shanghai.

Key Points: 
  • SHANGHAI, Aug. 1, 2023 /PRNewswire/ -- Dr. Robert H. Xiao, CEO of Perfect World and Perfect World E-sports & its platform segment, attended and addressed the 2023 Global Esports Conference on July 28 in Shanghai.
  • As a leading e-sports enterprise in China, Perfect World serves as the exclusive operator of DOTA 2 and CS:GO in the Chinese mainland.
  • Since 2015, Perfect World has successfully hosted three DOTA2 Asia Championships and, in 2019, assisted in organizing TI9 in Shanghai.
  • First, incorporating digital technologies such as AR/VR and AIGC in events to enhance the user experience.

Enhance Global Collaboration and Connectivity via E-Sports Competition: Perfect World CEO

Retrieved on: 
Tuesday, August 1, 2023
General Administration of Sport of China, Hangzhou, Social, DOTA, Perfect World, Culture, CS, Multimedia, IP, TI9, Sport, Development, Conference, AR, DOTA 2, Tourism, Creative industries, Entertainment, Online shopping

SHANGHAI, Aug. 1, 2023 /PRNewswire/ -- Dr. Robert H. Xiao, CEO of Perfect World and Perfect World E-sports & its platform segment, attended and addressed the 2023 Global Esports Conference on July 28 in Shanghai.

Key Points: 
  • SHANGHAI, Aug. 1, 2023 /PRNewswire/ -- Dr. Robert H. Xiao, CEO of Perfect World and Perfect World E-sports & its platform segment, attended and addressed the 2023 Global Esports Conference on July 28 in Shanghai.
  • As a leading e-sports enterprise in China, Perfect World serves as the exclusive operator of DOTA 2 and CS:GO in the Chinese mainland.
  • Since 2015, Perfect World has successfully hosted three DOTA2 Asia Championships and, in 2019, assisted in organizing TI9 in Shanghai.
  • First, incorporating digital technologies such as AR/VR and AIGC in events to enhance the user experience.

LRQA Chairman Martin Blackburn Spearheads Sustainable Growth and Partnerships during UAE Visit

Retrieved on: 
Friday, July 7, 2023
General Administration of Sport of China, E, Telecommunications, North America Western Asia Holdings, Electricity, General Administration of Customs, Business, Nuclear energy, Industrialisation, Diplomatic mission, Risk, LRQA, ESG, Commercial, Etisalat by e&, Drug, Renewable energy, Management, Assessment, Computer security

DUBAI, UAE, July 7, 2023 /PRNewswire/ -- LRQA's Chairman Martin Blackburn visited the UAE, heading a delegation of LRQA colleagues that held meetings with various clients, local partners, as well as internal work meetings with the Assessments and Inspection teams.

Key Points: 
  • DUBAI, UAE, July 7, 2023 /PRNewswire/ -- LRQA's Chairman Martin Blackburn visited the UAE, heading a delegation of LRQA colleagues that held meetings with various clients, local partners, as well as internal work meetings with the Assessments and Inspection teams.
  • Martin accompanied by Luis Cunha, Regional Director and Ayman Ktaily, Country Lead attended a ceremony hosted by H.E Rashed Lahej Al Mansoori, Director General, General Administration of Customs.
  • 24 certifications from LRQA were on display that Abu Dhabi Customs had achieved for their management systems.
  • He is involved in multiple capacities with several UAE companies, and we look forward to strengthening this relationship.